Chu Y, et al. - Researchers analyzed evidence from prospective cohort studies reporting the link between pentraxin-3 level and adverse outcomes in patients with coronary artery disease (CAD), to ultimately assess the prognostic significance of circulating pentraxin-3 level in CAD patients. Nine studies with 5,174 CAD patients were included in this meta-analysis. These studies were identified from Pubmed, Embae, CNKI, Wanfang, and VIP database searched from inception to January 10, 2019. An increased risk of all-cause mortality, cardiac death, and cardiac events was seen among CAD patients with the highest pentraxin-3 level; in the stable CAD subgroup, no significantly increased risk of cardiac events was found in relation to an elevated pentraxin-3 level. Overall, they concluded that elevated circulating pentraxin-3 level could be an independent predictor of all-cause mortality, cardiac death, and cardiac events in CAD patients.